Small molecule inhibitors and monoclonal antibodies against various member of this family have proven efficacy in different cancer settings, such as EGFR inhibitors in KRAS-wild type lung cancer and HER2 antibodies in HER2 positive breast cancer [125]. Here, ERBB2 is linked to breast cancer.